$10.09 Million in Sales Expected for Nurix Therapeutics, Inc. (NASDAQ:NRIX) This Quarter

Brokerages expect Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) to report sales of $10.09 million for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Nurix Therapeutics’ earnings, with estimates ranging from $8.00 million to $11.54 million. Nurix Therapeutics posted sales of $7.09 million during the same quarter last year, which indicates a positive year-over-year growth rate of 42.3%. The business is expected to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Nurix Therapeutics will report full year sales of $50.48 million for the current year, with estimates ranging from $33.62 million to $72.16 million. For the next financial year, analysts expect that the company will post sales of $73.56 million, with estimates ranging from $43.20 million to $108.12 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Nurix Therapeutics.

Nurix Therapeutics (NASDAQ:NRIX – Get Rating) last announced its quarterly earnings data on Thursday, April 7th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.06). Nurix Therapeutics had a negative net margin of 394.21% and a negative return on equity of 38.11%. The firm had revenue of $9.62 million for the quarter, compared to analysts’ expectations of $8.77 million.

NRIX has been the topic of several recent research reports. Zacks Investment Research raised Nurix Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 9th. Wells Fargo & Company decreased their price objective on Nurix Therapeutics from $28.00 to $25.00 and set an “equal weight” rating on the stock in a report on Monday, April 11th. HC Wainwright cut their price objective on Nurix Therapeutics from $62.00 to $60.00 and set a “buy” rating on the stock in a research report on Thursday, April 14th. Royal Bank of Canada dropped their target price on Nurix Therapeutics from $42.00 to $39.00 and set an “outperform” rating on the stock in a report on Monday, April 18th. Finally, Robert W. Baird decreased their price objective on shares of Nurix Therapeutics from $49.00 to $41.00 in a research note on Friday, January 28th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $46.17.

NASDAQ NRIX opened at $9.98 on Monday. The business has a 50-day moving average price of $12.50 and a 200-day moving average price of $19.87. Nurix Therapeutics has a twelve month low of $8.40 and a twelve month high of $37.42. The firm has a market cap of $448.60 million, a price-to-earnings ratio of -3.27 and a beta of 2.59.

Several large investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company boosted its holdings in shares of Nurix Therapeutics by 307.2% during the 1st quarter. The Manufacturers Life Insurance Company now owns 66,700 shares of the company’s stock worth $943,000 after buying an additional 50,318 shares during the period. Nomura Holdings Inc. raised its holdings in Nurix Therapeutics by 72.8% during the 1st quarter. Nomura Holdings Inc. now owns 305,340 shares of the company’s stock worth $4,265,000 after buying an additional 128,674 shares during the period. Alyeska Investment Group L.P. raised its holdings in Nurix Therapeutics by 5.0% during the 1st quarter. Alyeska Investment Group L.P. now owns 120,750 shares of the company’s stock worth $1,692,000 after buying an additional 5,750 shares during the period. Quantbot Technologies LP raised its holdings in shares of Nurix Therapeutics by 211.1% in the first quarter. Quantbot Technologies LP now owns 5,600 shares of the company’s stock valued at $78,000 after purchasing an additional 3,800 shares during the last quarter. Finally, Ensign Peak Advisors Inc boosted its position in Nurix Therapeutics by 1,634.1% during the first quarter. Ensign Peak Advisors Inc now owns 84,797 shares of the company’s stock worth $1,188,000 after purchasing an additional 79,907 shares during the period. 89.94% of the stock is owned by institutional investors.

Nurix Therapeutics Company Profile (Get Rating)

Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

See Also